IBX 3.53% 8.2¢ imagion biosystems limited

Ann: Imagion Announces Positive Results from Phase 1 Study, page-33

  1. 27,102 Posts.
    lightbulb Created with Sketch. 3162
    I am in this for every part of this tech, being taken out by a predator.
    MRX, MRI. / Contrast. Multiple cancer types, where ever the NPs can get to.

    Just because MRX has taken a back seat for now, does not remove its forward value from a takeover perspective.

    We have shown safety in human use in our phase 1 trial. A pretty big deal for going forward with.

    A market whipped this in the med tech sphere from here to 200m mc, previously.
    Ask Why ?

    While MRI offers that faster route to commercial hardware, the MRX has substantial legs for a predator to peruse, as well the third party applications. At a micro cap, the valuation needs to float with the forwards agenda after the impatient have left the building, without the covid delays that trapped the phase 1 trial.

    Bring on say a partnering with the HER2 phase 2 trial, and if i was calling the shots, start pushing other cancer types / partnering ??

    A lot to like, speculatively at this end of the med tech pricing, regards to how markets can swing when a registry is flushed, and replaced with a more competent management to push us forwards.

    Gamble well. Not investment advice.
 
watchlist Created with Sketch. Add IBX (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
-0.003(3.53%)
Mkt cap ! $2.677M
Open High Low Value Volume
8.2¢ 8.5¢ 8.2¢ $5.687K 69.23K

Buyers (Bids)

No. Vol. Price($)
1 4200 8.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 1000 1
View Market Depth
Last trade - 14.30pm 25/06/2024 (20 minute delay) ?
IBX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.